Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma

Arthritis and Rheumatism

Volumn 54, Issue 8, 2006, Pages 2626-2631

  Zhou, Xiaodong ^a   Tan, Filemon K ^a   Guo, Xinjian ^a   Arnett, Frank C ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; CONNECTIVE TISSUE GROWTH FACTOR; OSTEONECTIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ARTICLE; CASE REPORT; CELL ACTIVATION; COL1A2 GENE; COL3A1 GENE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CTGF GENE; EXTRACELLULAR MATRIX; GENE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN FIBROBLAST; SMAD3 GENE; SPARC GENE; SYSTEMIC SCLEROSIS; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; BIOLOGICAL MARKERS; CELLS, CULTURED; COLLAGEN TYPE I; COLLAGEN TYPE II; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; OSTEONECTIN; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, SMALL INTERFERING; SCLERODERMA, SYSTEMIC; SKIN; TRANSFECTION;

EID: 33746945984     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21973     Document Type: Article

References (15)

1. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma: the myth of the "uninvolved skin." Arthritis Rheum 1991;34:1495-501.
2. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-13.
3. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
4. Zhou X, Tan FK, Reveille JD, Wallis D, Milewicz DM, Ahn C, et al. Association of novel polymorphisms with the expression of SPARC in normal fibroblasts and with susceptibility to scleroderma. Arthritis Rheum 2002;46:2990-9.
5. Unemori EN, Amento EP. Connective tissue metabolism including cytokines in scleroderma. Curr Opin Rheumatol 1991; 3:953-9.
6. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001;19: 816-27.
7. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, Sage EH. SPARC regulates the expression of collagen type I and transforming growth factor-β1 in mesangial cells. J Biol Chem 1999;274:32145-52.
8. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Mol Biol Cell 2003;14:3977-88.
9. Trojanowska M. Molecular aspects of scleroderma. Front Biosci 2002;7:d608-18.
10. Strandjord TP, Madtes DK, Weiss DJ, Sage EH. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol 1999;277:L628-35.
11. Zhou X, Tan FK, Guo X, Wallis D, Milewicz DM, Xue S, et al. Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor β1 in cultured normal human fibroblasts. Arthritis Rheum 2005;52:257-61.
12. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
14. Wallis DD, Tan FK, Kielty CM, Kimball MD, Arnett FC, Milewicz DM. Abnormalities in fibrillin 1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001;44:1855-64.
15. Zhou X, Tan FK, Milewicz DM, Guo X, Bona CA, Arnett FC. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-β pathway to recapitulate the "scleroderma phenotype." J Immunol 2005;175:4555-60.